What is Filana Therapeutics, Inc.'s earnings per share (EPS)?

Filana Therapeutics, Inc. (FLNA) reported diluted earnings per share of -$1.88 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Filana Therapeutics, Inc. (FLNA) Financials

FLNA

FY2025 annual

Net Income -$91.0M -273.7% YoY

EPS (Diluted) -$1.88 YoY not available

Free Cash Flow -$32.8M +71.9% YoY

Operating Cash Flow -$32.3M +72.4% YoY

Market Cap $35.1M as of Sep 19, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.5x on $68.1M equity, Q1 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FLNA SEC filings page.

This page shows Filana Therapeutics, Inc. (FLNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FLNA FY2025 2026-08-29

Filana's dominant mechanic is a research-driven cash draw: spending has contracted, while financing capacity and balance-sheet cushion have also narrowed.

The key earnings-quality shift is that FY2025 operating cash flow was -$32.3M against a net loss of -$91.0M, whereas FY2024 cash flow was -$116.9M against a much smaller loss. The near-match between FY2025 free cash flow of -$32.8M and operating cash flow indicates that capital spending was not the main cash drain; the larger change was the relationship between accounting results and cash movement.

The FY2025 operating loss narrowed to -$95.4M as research and development fell to $26.6M, indicating a much smaller reported development commitment. Yet net loss was -$91.0M versus -$24.3M in FY2024, so lower development spending did not translate into a comparable bottom-line improvement.

Liabilities rose to $44.0M while equity fell to $74.4M, making the balance sheet less equity-cushioned. Debt-to-equity rose to 0.6x from 0.1x, while the reported liquidity comparison of 35.5 months coexisted with a current ratio of 2.2x, separating reported resources from broad short-term flexibility.

Financial Health Signals

Financial health score not available

Filana Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Filana Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Filana Therapeutics, Inc. reported a net loss of $91.0M while operations used $32.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$10.9M

YoY+55.2%

Filana Therapeutics, Inc.'s EBITDA was -$10.9M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.2% from the same quarter a year earlier.

Net Income

-$10.3M

YoY+55.9%

Filana Therapeutics, Inc. reported -$10.3M in net income in Q1 2026. This represents an increase of 55.9% from the same quarter a year earlier.

Revenue

Not reported for Q1 2026.

EPS (Diluted)

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$86.6M

YoY-26.2%

QoQ-9.3%

5Y CAGR-21.0%

10Y CAGR+12.5%

Filana Therapeutics, Inc. held $86.6M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

48M

YoY0.0%

QoQ0.0%

5Y CAGR+3.8%

10Y CAGR+0.5%

Filana Therapeutics, Inc. had 48M shares outstanding in Q1 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-15.2%

YoY+3.2pp

Filana Therapeutics, Inc.'s ROE was -15.2% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 3.2 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$4.5M

YoY-66.7%

Filana Therapeutics, Inc. invested $4.5M in research and development in Q1 2026. This represents a decrease of 66.7% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

FLNA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FLNA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$41.1M+277.6%	$10.9M-5.2%	$11.5M
R&D Expenses	N/A	$26.6M-61.8%	$69.6M-22.1%	$89.4M+31.4%	$68.0M+174.2%	$24.8M	N/A	N/A	$3.0M-61.0%	$7.6M-17.0%	$9.2M+0.8%	$9.1M+24.6%	$7.3M+48.6%	$4.9M-35.3%	$7.6M-8.4%	$8.3M
SG&A Expenses	N/A	$68.8M-4.2%	$71.8M+334.3%	$16.5M+37.9%	$12.0M+48.8%	$8.1M+115.4%	$3.7M+10.3%	$3.4M-8.2%	$3.7M-14.8%	$4.3M-25.0%	$5.8M+13.3%	$5.1M-0.5%	$5.1M+6.0%	$4.8M-32.7%	$7.2M+7.2%	$6.7M
Operating Income	N/A	-$95.4M+32.6%	-$141.4M-33.5%	-$106.0M-32.4%	-$80.0M-143.5%	-$32.9M-409.9%	-$6.4M-30.0%	-$5.0M+25.6%	-$6.7M+44.2%	-$11.9M+20.1%	-$15.0M-5.3%	-$14.2M-14.2%	-$12.4M-139.6%	$31.4M+904.8%	-$3.9M-10.9%	-$3.5M
EBITDA	N/A	-$94.5M+32.7%	-$140.3M-34.4%	-$104.4M-32.7%	-$78.7M-143.5%	-$32.3M-403.3%	-$6.4M-31.1%	-$4.9M+25.7%	-$6.6M+44.5%	-$11.9M+20.3%	-$14.9M-5.2%	-$14.2M-14.0%	-$12.4M	N/A	-$3.8M-12.7%	-$3.4M
Income Tax	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$73K	$0	$0
Net Income	N/A	-$91.0M-273.7%	-$24.3M+75.0%	-$97.2M-27.5%	-$76.2M-135.4%	-$32.4M-411.3%	-$6.3M-36.8%	-$4.6M+29.4%	-$6.6M+45.0%	-$11.9M+19.8%	-$14.8M-5.0%	-$14.1M-14.2%	-$12.4M-139.3%	$31.5M+1015.4%	-$3.4M-31.9%	-$2.6M
EPS (Basic)	N/A	-$1.88-254.7%	-$0.53+77.2%	-$2.32-22.1%	-$1.90-131.7%	-$0.82	N/A	N/A	N/A	N/A	N/A	-$0.31-14.8%	-$0.27-138.6%	$0.70+975.0%	-$0.08-33.3%	-$0.06
EPS (Diluted)	—	-$1.88	-$1.46	-$2.32-22.1%	-$1.90	N/A	N/A	N/A	N/A	N/A	N/A	-$0.31-14.8%	-$0.27-138.6%	$0.70+975.0%	-$0.08-33.3%	-$0.06
Diluted Shares (Avg)	N/A	48M	47M	42M+4.3%	40M	N/A	N/A	N/A	N/A	N/A	N/A	46M+1.1%	45M+0.1%	45M+1.0%	45M+1.3%	44M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
R&D Expenses	$4.5M-66.7%	N/A	$4.0M-77.6%	$5.1M-66.3%	$13.7M-15.8%	N/A	$17.7M-25.1%	$15.2M-39.1%
SG&A Expenses	$6.6M-39.3%	N/A	$7.9M-38.9%	$40.3M-12.8%	$10.9M+195.1%	N/A	$12.9M+202.8%	$46.2M+1113.3%
Operating Income	-$11.2M+54.6%	N/A	-$11.9M+61.3%	-$45.4M+26.1%	-$24.6M-23.3%	N/A	-$30.6M-9.8%	-$61.4M-113.4%
EBITDA	-$10.9M+55.2%	N/A	-$11.7M+61.6%	-$45.2M+26.0%	-$24.4M-24.6%	N/A	-$30.4M-10.6%	-$61.0M-115.1%
Income Tax	$0	N/A	$0	$0	$0	N/A	$0	$0
Net Income	-$10.3M+55.9%	N/A	-$10.8M+61.3%	-$44.2M-818.5%	-$23.4M-193.5%	N/A	-$27.9M-8.9%	$6.2M+123.3%
EPS (Basic)	-$0.21+56.3%	-$0.26+56.7%	-$0.22+62.1%	-$0.92-807.7%	-$0.48-182.8%	-$0.60-20.0%	-$0.58+4.9%	$0.13+120.6%
EPS (Diluted)	N/A	-$0.26+55.2%	-$0.22+62.1%	-$0.92-807.7%	-$0.48-11.6%	-$0.58-16.0%	-$0.58+4.9%	$0.13+120.6%
Diluted Shares (Avg)	N/A	N/A	48M+0.7%	48M+4.6%	48M+9.4%	N/A	48M+14.2%	46M+10.5%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

FLNA Balance Sheet

FLNA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$118.4M-24.9%	$157.5M+3.9%	$151.7M-35.4%	$234.8M-12.0%	$266.8M+182.9%	$94.3M+301.5%	$23.5M+16.6%	$20.1M+85.9%	$10.8M-43.9%	$19.3M-39.5%	$31.9M-22.0%	$40.9M-18.4%	$50.1M-11.9%	$56.9M-42.5%	$99.0M
Current Assets	$97.7M-28.4%	$136.5M+5.3%	$129.6M-38.6%	$211.2M-13.6%	$244.5M+160.1%	$94.0M+302.6%	$23.3M+16.5%	$20.0M+87.9%	$10.7M-44.1%	$19.1M-39.8%	$31.7M-22.4%	$40.8M-18.5%	$50.1M-11.3%	$56.5M-42.6%	$98.5M
Cash & Equivalents	$95.5M-25.7%	$128.6M+6.1%	$121.1M-39.7%	$201.0M-13.9%	$233.4M+149.6%	$93.5M+305.1%	$23.1M+16.5%	$19.8M+89.0%	$10.5M-36.9%	$16.6M-46.9%	$31.3M-22.9%	$40.6M-16.5%	$48.6M-1.6%	$49.4M-32.5%	$73.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$2.1M	$0	$0-100.0%	$1.3M-81.9%	$6.9M-72.4%	$25.0M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$44.0M+271.6%	$11.8M-16.7%	$14.2M+94.6%	$7.3M-43.3%	$12.9M+512.7%	$2.1M+51.4%	$1.4M+171.4%	$511K-54.9%	$1.1M+70.2%	$665K-73.9%	$2.6M+200.1%	$850K-52.8%	$1.8M-95.9%	$43.7M-19.9%	$54.6M
Current Liabilities	$43.8M+273.1%	$11.8M-17.2%	$14.2M+101.0%	$7.1M-43.6%	$12.5M+572.1%	$1.9M+34.5%	$1.4M+171.4%	$511K-54.9%	$1.1M+70.2%	$665K-73.9%	$2.6M+200.1%	$850K-52.8%	$1.8M-82.0%	$10.0M-24.7%	$13.3M
Non-Current Liabilities	$118K+49.4%	$79K	$0-100.0%	$232K-30.3%	$333K+41.7%	$235K	$0	$0	$0	$0	$0	$0	$0-100.0%	$33.7M-18.3%	$41.3M
Total Equity	$74.4M-48.9%	$145.7M+6.0%	$137.5M-39.6%	$227.5M-10.4%	$253.9M+175.4%	$92.2M+317.2%	$22.1M+12.6%	$19.6M+102.4%	$9.7M-48.0%	$18.6M-36.5%	$29.4M-26.7%	$40.1M-17.1%	$48.3M+267.7%	$13.1M-70.4%	$44.4M
Retained Earnings	-$496.1M-22.5%	-$405.1M-6.4%	-$380.8M-34.3%	-$283.6M-36.8%	-$207.3M-18.5%	-$174.9M-3.8%	-$168.6M-2.8%	-$164.0M-4.2%	-$157.4M-8.2%	-$145.5M-11.4%	-$130.6M-12.1%	-$116.5M-11.9%	-$104.1M+23.3%	-$135.7M-2.6%	-$132.2M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$108.4M-23.1%	$118.4M-24.9%	$129.7M-42.0%	$135.4M-44.4%	$140.9M-9.5%	$157.5M+3.9%	$223.8M+29.7%	$243.6M+23.5%
Current Assets	$88.0M-26.8%	$97.7M-28.4%	$108.9M-46.2%	$114.8M-48.3%	$120.2M-10.3%	$136.5M+5.3%	$202.5M+34.9%	$222.1M+27.3%
Cash & Equivalents	$86.6M-26.2%	$95.5M-25.7%	$106.1M-28.8%	$112.4M-45.8%	$117.3M-5.5%	$128.6M+6.1%	$149.0M+4.7%	$207.3M+23.1%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$40.2M+202.1%	$44.0M+271.6%	$48.2M-15.7%	$47.4M-13.2%	$13.3M-82.7%	$11.8M-16.7%	$57.1M+228.0%	$54.6M+205.1%
Current Liabilities	$40.1M+203.1%	$43.8M+273.1%	$48.0M-15.8%	$47.3M-13.3%	$13.2M-82.8%	$11.8M-17.2%	$57.0M+227.5%	$54.6M+205.1%
Non-Current Liabilities	$111K+40.5%	$118K+49.4%	$119K+48.8%	$79K	$79K	$79K	$80K	$0
Total Equity	$68.1M-46.6%	$74.4M-48.9%	$81.6M-51.1%	$88.0M-53.4%	$127.6M+62.4%	$145.7M+6.0%	$166.6M+7.4%	$189.0M+5.4%
Retained Earnings	-$506.4M-18.2%	-$496.1M-22.5%	-$483.5M-28.1%	-$472.7M-35.2%	-$428.5M-20.5%	-$405.1M-6.4%	-$377.5M-4.9%	-$349.6M-4.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

FLNA Cash Flow Statement

FLNA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$29.8M	-$32.3M+72.4%	-$116.9M-42.6%	-$82.0M-5.8%	-$77.5M-156.7%	-$30.2M-461.1%	-$5.4M-114.1%	-$2.5M+47.3%	-$4.8M+42.1%	-$8.2M+32.7%	-$12.2M-35.1%	-$9.1M+5.2%	-$9.5M-37.5%	-$6.9M+3.1%	-$7.2M-2658.1%	-$260K
Depreciation & Amortization	N/A	$936K-17.3%	$1.1M-26.0%	$1.5M+17.6%	$1.3M+143.6%	$534K+2327.3%	$22K-62.1%	$58K-15.9%	$69K+1.5%	$68K+17.2%	$58K+28.9%	$45K+200.0%	$15K	N/A	$122K-25.2%	$163K
Stock-Based Compensation	N/A	$19.6M+20.2%	$16.3M+255.2%	$4.6M+122.0%	$2.1M+17.5%	$1.8M+78.0%	$988K-23.8%	$1.3M-45.7%	$2.4M-19.7%	$3.0M-31.4%	$4.3M+25.4%	$3.5M-8.1%	$3.8M+21.3%	$3.1M-53.1%	$6.6M+21.8%	$5.4M
Capital Expenditures	N/A	$581K+464.1%	$103K-75.1%	$414K-84.7%	$2.7M-87.8%	$22.2M	N/A	$18K	N/A	N/A	$75K-61.5%	$195K+143.8%	$80K	N/A	N/A	N/A
Free Cash Flow	N/A	-$32.8M+71.9%	-$117.0M-42.0%	-$82.4M-2.8%	-$80.2M-53.1%	-$52.4M	N/A	-$2.5M	N/A	N/A	-$12.3M-33.1%	-$9.2M+4.0%	-$9.6M	N/A	N/A	N/A
Investing Cash Flow	N/A	-$581K-464.1%	-$103K+75.1%	-$414K+84.7%	-$2.7M+87.8%	-$22.2M-6270.6%	$360K+2100.0%	-$18K	N/A	$2.1M+197.0%	-$2.2M	N/A	N/A	N/A	$17.6M-70.6%	$59.9M
Financing Cash Flow	-$380K	-$239K-100.2%	$124.5M+4762.1%	$2.6M-94.6%	$47.8M-75.1%	$192.3M+154.9%	$75.4M+1199.5%	$5.8M-58.8%	$14.1M	N/A	-$284K	N/A	N/A	N/A	-$34.2M-493.4%	$8.7M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$8.9M+21.7%	-$9.7M+84.1%	-$6.2M+66.0%	-$4.9M+72.9%	-$11.3M+40.7%	-$61.3M-174.5%	-$18.3M+31.0%	-$18.2M+8.4%
Depreciation & Amortization	$243K+10.5%	$334K+198.2%	$200K-13.8%	$200K-43.8%	$220K-40.9%	$112K-68.5%	$232K-40.8%	$356K-9.0%
Stock-Based Compensation	$4.1M-22.1%	N/A	$4.4M-21.5%	$4.6M+76.0%	$5.2M+123.8%	N/A	$5.6M+491.0%	$2.6M+211.9%
Capital Expenditures	N/A	$501K+778.9%	$80K+370.6%	$0-100.0%	$0	$57K+39.0%	$17K-22.7%	$29K+383.3%
Free Cash Flow	N/A	-$10.2M+83.3%	-$6.3M+65.6%	-$4.9M+72.9%	-$11.3M+40.7%	-$61.3M-174.3%	-$18.3M+31.0%	-$18.3M+8.3%
Investing Cash Flow	N/A	-$501K-778.9%	-$80K-370.6%	$0+100.0%	$0	-$57K-39.0%	-$17K+22.7%	-$29K-583.3%
Financing Cash Flow	-$51K-156.7%	-$329K-135.8%	$0	$0-100.0%	$90K-99.6%	$918K-19.7%	$0-100.0%	$101.4M+11305.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

FLNA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FLNA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	76.3%+112.1pp	-35.8%-5.2pp	-30.6%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	76.7%+108.3pp	-31.6%-8.9pp	-22.8%
Return on Equity	-122.3%-105.6pp	-16.7%+54.0pp	-70.7%-37.2pp	-33.5%-20.8pp	-12.8%-5.9pp	-6.9%+14.1pp	-21.0%+12.4pp	-33.4%+89.4pp	-122.8%-43.1pp	-79.7%-31.5pp	-48.2%-17.3pp	-30.9%-96.2pp	65.3%+91.5pp	-26.2%-20.3pp	-5.9%
Return on Assets	-76.9%-61.4pp	-15.4%+48.7pp	-64.1%-31.6pp	-32.5%-20.3pp	-12.1%-5.4pp	-6.7%+13.0pp	-19.7%+12.8pp	-32.6%+77.4pp	-110.0%-33.0pp	-76.9%-32.6pp	-44.3%-14.0pp	-30.3%-93.2pp	63.0%+69.0pp	-6.1%-3.4pp	-2.6%
Current Ratio	2.23-9.4x	11.62+2.5x	9.13-20.8x	29.91+10.4x	19.51-30.9x	50.40+33.6x	16.83-22.4x	39.22+29.8x	9.42-19.3x	28.68+16.3x	12.42-35.6x	48.03+20.2x	27.82+22.2x	5.65-1.8x	7.42
Debt-to-Equity	0.59+0.5x	0.080.0x	0.10+0.1x	0.030.0x	0.050.0x	0.020.0x	0.060.0x	0.03-0.1x	0.12+0.1x	0.04-0.1x	0.09+0.1x	0.020.0x	0.04-3.3x	3.33+2.1x	1.23
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.82+0.6x	0.19+0.1x	0.12

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Return on Equity	-15.2%+3.2pp	N/A	-13.3%+3.5pp	-50.3%-53.5pp	-18.3%-50.2pp	N/A	-16.8%-0.2pp	3.3%+18.0pp
Return on Assets	-9.5%+7.1pp	N/A	-8.3%+4.2pp	-32.7%-35.2pp	-16.6%-32.7pp	N/A	-12.5%+2.4pp	2.5%+15.9pp
Current Ratio	2.19-6.9x	2.23-9.4x	2.27-1.3x	2.43-1.6x	9.08+7.3x	11.62+2.5x	3.55-5.1x	4.07-5.7x
Debt-to-Equity	0.59+0.5x	0.59+0.5x	0.59+0.2x	0.54+0.3x	0.10-0.9x	0.080.0x	0.34+0.2x	0.29+0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Where Filana Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Filana Therapeutics, Inc. profitable?

No, Filana Therapeutics, Inc. (FLNA) reported a net income of -$91.0M in fiscal year 2025.

What is Filana Therapeutics, Inc.'s EBITDA?

Filana Therapeutics, Inc. (FLNA) had EBITDA of -$94.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Filana Therapeutics, Inc.'s return on equity (ROE)?

Filana Therapeutics, Inc. (FLNA) has a return on equity of -122.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Filana Therapeutics, Inc.'s free cash flow?

Filana Therapeutics, Inc. (FLNA) recorded an outflow of $32.8M in free cash flow during fiscal year 2025. This represents a 71.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Filana Therapeutics, Inc.'s operating cash flow?

Filana Therapeutics, Inc. (FLNA) recorded an outflow of $32.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Filana Therapeutics, Inc.'s total assets?

Filana Therapeutics, Inc. (FLNA) had $118.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Filana Therapeutics, Inc.'s capital expenditures?

Filana Therapeutics, Inc. (FLNA) invested $581K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Filana Therapeutics, Inc. spend on research and development?

Filana Therapeutics, Inc. (FLNA) invested $26.6M in research and development during fiscal year 2025.

How many shares does Filana Therapeutics, Inc. have outstanding?

Filana Therapeutics, Inc. (FLNA) had 48M shares outstanding as of fiscal year 2025.

What is Filana Therapeutics, Inc.'s current ratio?

Filana Therapeutics, Inc. (FLNA) had a current ratio of 2.23 as of fiscal year 2025, which is generally considered healthy.

What is Filana Therapeutics, Inc.'s debt-to-equity ratio?

Filana Therapeutics, Inc. (FLNA) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Filana Therapeutics, Inc.'s return on assets (ROA)?

Filana Therapeutics, Inc. (FLNA) had a return on assets of -76.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Filana Therapeutics, Inc.'s P/E ratio?

Filana Therapeutics, Inc. (FLNA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $35.1M as of Sep 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Filana Therapeutics, Inc.'s price-to-sales ratio?

Filana Therapeutics, Inc. (FLNA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $35.1M as of Sep 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Filana Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Filana Therapeutics, Inc. (FLNA) held $95.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $32.3M over that year. Dividing the one by the other, the reported balance equals about 36 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Filana Therapeutics, Inc.'s Piotroski F-Score?

Filana Therapeutics, Inc. (FLNA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Filana Therapeutics, Inc.'s earnings high quality?

Filana Therapeutics, Inc. (FLNA) reported a net loss of $91.0M while operations used $32.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.